Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity

Toxicology and Applied Pharmacology
Jin Kyung LeeKim L R Brouwer

Abstract

Trabectedin is a promising anticancer agent, but dose-limiting hepatotoxicity was observed during phase I/II clinical trials. Dexamethasone (DEX) has been shown to significantly reduce trabectedin-mediated hepatotoxicity. The current study was designed to assess the capability of sandwich-cultured primary rat hepatocytes (SCRH) to predict the hepato-protective effect of DEX against trabectedin-mediated cytotoxicity. The role of multidrug resistance-associated protein 2 (Mrp2; Abcc2) in trabectedin hepatic disposition also was examined. In SCRH from wild-type Wistar rats, cytotoxicity was observed after 24-h continuous exposure to trabectedin. SCRH pretreated with additional DEX (1 microM) exhibited a 2- to 3-fold decrease in toxicity at 100 nM and 1000 nM trabectedin. Unexpectedly, toxicity in SCRH from Mrp2-deficient (TR(-)) compared to wild-type Wistar rats was markedly reduced. Depletion of glutathione from SCRH using buthionine sulfoximine (BSO) mitigated trabectedin toxicity associated with 100 nM and 1000 nM trabectedin. Western blot analysis demonstrated increased levels of CYP3A1/2 and Mrp2 in SCRH pretreated with DEX; interestingly, Mrp4 expression was increased in SCRH after BSO exposure. Trabectedin biliary recovery ...Continue Reading

References

Jul 1, 1996·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·S C LuN Kaplowitz
Jan 1, 1996·Pharmaceutical Biotechnology·E L LeCluyseJ H Hochman
Jan 1, 1996·Pharmaceutical Biotechnology·K L Brouwer, R G Thurman
Jun 1, 1997·The Journal of Laboratory and Clinical Medicine·J GeorgeG C Farrell
Jun 1, 1997·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·C C PaulusmaR P Oude Elferink
Nov 18, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E IzbickaD D Von Hoff
May 18, 1999·The Journal of Biological Chemistry·T HirohashiY Sugiyama
Jan 25, 2000·The Journal of Biological Chemistry·T HirohashiY Sugiyama
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S DelalogeE Cvitkovic
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A TaammaE Cvitkovic
Feb 22, 2002·Journal of the American Society of Nephrology : JASN·Rémon A M H van AubelFrans G M Russel
Jul 2, 2003·Proceedings of the National Academy of Sciences of the United States of America·Glen ReidPiet Borst
Jul 29, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Maria RiusDietrich Keppler
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A YovineJ L Misset
Jun 5, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J-Y BlayI Judson
Jul 20, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Ryan Z TurncliffKim L R Brouwer
Sep 30, 2004·American Journal of Physiology. Renal Physiology·Rémon A M H Van AubelFrans G M Russel
Jun 3, 2005·Nature Reviews. Drug Discovery·Neil Kaplowitz
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R Garcia-CarboneroG D Demetri
Sep 1, 2005·Investigational New Drugs·J H BeumerJ H M Schellens
Oct 6, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Brendan M JohnsonKim L R Brouwer
Nov 8, 2005·Biochemical Pharmacology·Vanessa M SilvaJosé E Manautou
Nov 8, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Ian S WestleyBenedetta C Sallustio
Feb 4, 2006·Current Drug Metabolism·Quan TianShu-Feng Zhou
Jun 2, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F GrossoP G Casali
Jul 19, 2006·Pflügers Archiv : European journal of physiology·Anne T Nies, Dietrich Keppler
Jul 22, 2006·The Journal of Pharmacology and Experimental Therapeutics·Maciej J Zamek-GliszczynskiKim L R Brouwer
Sep 22, 2006·Cancer Chemotherapy and Pharmacology·Jan H BeumerJos H Beijnen

❮ Previous
Next ❯

Citations

Oct 29, 2013·Annual Review of Pharmacology and Toxicology·Nathan D PfeiferKim L R Brouwer
Feb 25, 2009·Investigational New Drugs·J H BeumerO van Tellingen
Sep 12, 2014·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Christian LeporiniEmilio Russo
Feb 16, 2011·The Journal of Pharmacology and Experimental Therapeutics·Grace Zhixia YanMary F Paine
Feb 2, 2013·Drug Metabolism Reviews·Eva RamboerMathieu Vinken
Apr 13, 2010·Expert Opinion on Drug Metabolism & Toxicology·Qin Meng
Mar 5, 2013·Expert Opinion on Drug Metabolism & Toxicology·Tom De BruynPieter Annaert
Jan 20, 2010·Drug Metabolism Reviews·Katalin JemnitzPeter Krajcsi
Mar 18, 2010·Drug Metabolism Reviews·Xinsheng Gu, Jose E Manautou
Mar 31, 2009·Cancer Treatment Reviews·Xuemei CaiDaniel D Von Hoff
Mar 11, 2015·Toxicological Sciences : an Official Journal of the Society of Toxicology·Barbara A RoggenbeckElaine M Leslie
May 15, 2018·Clinical Pharmacology and Therapeutics·Raymond EversUNKNOWN International Transporter Consortium
Feb 20, 2010·Drugs·Natalie J Carter, Susan J Keam
Jun 6, 2009·Expert Review of Anticancer Therapy·Laurence BoudouPhilippe A Cassier
Aug 24, 2010·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·N M S de GrootM L Simoons
Sep 6, 2012·Clinical Pharmacology and Therapeutics·K Köck, K L R Brouwer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.